Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGOS: BMS-986489 + Chemo vs Atezolizumab + Chemo in First-Line ES-SCLC
NCT06646276Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of bms-986012 + nivolumab in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Started Feb 2025; status: recruiting.
02
Drugs
bms-986012 + nivolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06646276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646276.